key: cord-0753060-06kowddq
authors: Ciulla, Michele M
title: Switching to another antihypertensive effective drug when using ACEIs/ARBs to treat arterial hypertension during COVID-19
date: 2020-04-23
journal: Eur Heart J
DOI: 10.1093/eurheartj/ehaa331
sha: 35842f9b743e9929b9ce6670e6f390f22124f4c8
doc_id: 753060
cord_uid: 06kowddq

nan

I appreciated the well-argued paper by Kuster et al; however, it seems that the authors forget that, at least to treat arterial hypertension, we have the possibility to choose other effective drugs such as calcium channel blockers, an antihypertensive master class. 2 Indeed, even if there are no data supporting a causal relationship between angiotensin-converting enzyme 2 (ACE2) activity and COVID-19associated mortality, we should not underestimate the way in which SARS-CoV-2 enters the cell that is well documented with an entry risk map, based on expression of ACE2 that, coincidentally, follows the initial clinical presentation of COVID-19. 3 Furthermore, data updated on 20 March from the Italian Health Institute on a sample of 3200 deaths 4 support: (i) a high mortality rate for elderly subjects (mean age 78.5, median 80, range 31-103, IQR 73-85); (ii) high coexistence of comorbidities (98.7% have > _1 comorbidity); (iii) high blood pressure as the prevailing comorbidity since 73.8% of the subjects were hypertensives; and (iv) use of ACEIs/ARBs documented in 52% of deaths. We don't know if this is merely a coincidence and we do not have data on patients affected by COVID-19 that are receiving ACEIs/ARBs and their relative mortality rates in China; nonetheless, if we exclude subjects with heart failure and/or ischaemic heart disease, what would be the reason not to switch to another drug to treat high blood pressure, obviously, without destabilizing blood pressure control?

Conflict of interest: none declared.

SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?

Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection